Is metabolic syndrome associated to HIV infection per se? Results from the HERMES study

Department of Infectious Diseases, Luigi Sacco Hospital, via G.B. Grassi, 44, 20157 Milano, Italy.
Current HIV research (Impact Factor: 1.76). 02/2010; 8(2):165-71. DOI: 10.2174/157016210790442731
Source: PubMed


HERMES is a prospective study, including all treatment-naïve patients attending scheduled visits at hospitals in the CISAI group in 2007. The present cross-sectional analysis aims to assess the baseline prevalence and characteristics of Metabolic Syndrome (MS) in a population of HIV-positive treatment-naïve patients. MS was diagnosed using the National Cholesterol Education Program (NCEP) definitions. A total of 292 subjects were enrolled, median age was 37 years, 75% of them were males. The prevalence of MS was 12.3%. The most frequent trio of abnormalities that led to the diagnosis of MS was high blood pressure, triglycerides and HDL. Univariate analysis showed that MS was associated with the following variables: age, education, physical activity, advanced HIV disease (CDC stage C or HIV-RNA >100,000 copies + CD4 <100 cells/mm(3)). Higher educational levels remained protectively associated with MS in multivariate analysis. A higher risk of MS was also associated with advanced HIV disease. Actually, treatment-naïve HIV-positive patients in an advanced stage of the disease have a higher prevalence of abnormal levels of triglycerides, HDL cholesterol and blood glucose than those at a less advanced stage. These findings of the HERMES study suggest, therefore, that HIV infection per se is associated to MS.

1 Follower
36 Reads
  • Source
    • "However, it now appears clear that both HIV infection itself and cART are associated with a higher risk of stroke and metabolic disorders.3,4 In a cross-sectional study of 292 subjects, a CD4+ T-cell count less than 100 cells/mm3 was associated with a higher densirisk of metabolic syndrome.5 In parallel, metabolic complications were frequently observed after a few years of cART initiation.6 "
    [Show abstract] [Hide abstract]
    ABSTRACT: Purpose HIV-infected patients are at increased risk for cardiovascular disease, which may be mediated in part by inflammation. This study aimed to evaluate the risk factors of carotid plaque, and clinical factors associated with carotid atherosclerosis measured by carotid intima-medial thickness (cIMT) in HIV patients. Materials and Methods Clinical and cardiometabolic factors as well as cIMT were prospectively measured in 145 HIV-infected participants who had received combined antiretroviral therapy for ≥6 months. The mean value of the bilateral average cIMT level was used as Mean-IMT in the analysis, and the greatest value among the measured cIMT levels was used as Max-IMT. Results Among 145 patients, 34 (23.4%) had carotid plaque. Multivariate logistic regression analysis revealed three independent risk factors of carotid plaque: old age [odds ratio (OR) 6.16, 95% confidence interval (CI) 1.09-34.88; p=0.040], hypertension (OR 12.62, 95% CI 1.72-92.49; p=0.013) and higher low-density lipoprotein cholesterol (LDL-C) (OR 1.08, 95% CI 1.01-1.16; p=0.039). Levels of estimated glomerular filtration rate were inversely associated with Mean-IMT (r=-0.379, p<0.001) and Max-IMT (r=-0.389, p<0.001). Stepwise multivariate regression analyses revealed that age, total cholesterol and fasting glucose were positively correlated with cIMT, independent of other risk factors. Conclusion The presence of hypertension, old age and a higher level of LDL-C were independent risk factors of carotid plaque among HIV-infected subjects.
    Yonsei medical journal 07/2013; 54(4):990-998. DOI:10.3349/ymj.2013.54.4.990 · 1.29 Impact Factor
  • Source
    • "In view of in vitro evidence of altered expression of genes involved in lipid metabolism and fatty acid profiles of HIV-infected cells [20] [21] [22] [23] [24], of clinical evidence of disturbed plasma and tissue lipid concentrations in antiretroviral-naive HIV-1-infected patients [4] [13] [8] [14] [15] [9] [10] [16] [12], and of an increased plasma unesterified AA concentration and increased brain AA metabolism in 7–9 month old HIV-1 Tg rats [31], we hypothesized that lipid concentrations in different organs and plasma are altered in drug-free HIV-1 Tg rats compared to wild-type controls. To test this hypothesis, in the present study we measured concentrations of different lipids (including fatty acids) in liver, plasma, heart and brain of 7–9 month old wildtype and HIV-1 Tg rats fed a polyunsaturated fatty acid (PUFA)-sufficient diet free of AA and docosahexaenoic acid (DHA, 22:6nÀ 3) [31] [32]. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Disturbed lipid metabolism has been reported in antiretroviral-naive HIV-1-infected patients suggesting a direct effect of the virus on lipid metabolism. To test that the HIV-1 virus alone could alter lipid concentrations, we measured these concentrations in an HIV- 1 transgenic (Tg) rat model of human HIV-1 infection, which demonstrates peripheral and central pathology by 7-9 months of age. Concentrations were measured in high-energy microwaved heart, brain and liver from 7-9 month-old HIV-1 Tg and wildtype rats, and in plasma from non-microwaved rats. Plasma triglycerides and liver cholesteryl ester and total cholesterol concentrations were significantly higher in HIV-1 Tg rats than controls. Heart and plasma fatty acid concentrations reflected concentration differences in liver, which showed higher n-3 and n-6 polyunsaturated fatty acid (PUFA) concentrations in multiple lipid compartments. Fatty acid concentrations were increased or decreased in heart and liver phospholipid subfractions. Brain fatty acid concentrations differed significantly between the groups for minor fatty acids such as linoleic acid and n-3 docosapentaenoic acid. The profound changes in heart, plasma and liver lipid concentrations suggest a direct effect of chronic exposure to the HIV-1 virus on peripheral lipid (including PUFA) metabolism.
    Prostaglandins Leukotrienes and Essential Fatty Acids 08/2012; 87(4-5):91-101. DOI:10.1016/j.plefa.2012.07.006 · 2.35 Impact Factor

  • The Journal of infection 11/2010; 61(5):428-30. DOI:10.1016/j.jinf.2010.09.001 · 4.44 Impact Factor
Show more